MAP2K7 and melanoma: With the majority of melanomas exhibiting RAS-MEK activation through mutations in N-RasQ61R or BrafV600E[66], our findings in conjunction with these studies provide a compelling basis for further exploration of autophagy inhibition in combination with inhibition of RAS-MEK and PI3K/AKT/mTOR signaling, two of the most dysregulated pathways in melanoma.